Role of melanoma secreted thrombospondin-1 on induction of immunosuppressive regulatory T cells through CD47

Journal of Cancer Molecules

Volumn 4, Issue 5, 2008, Pages 145-152

  Baumgartner, Joel M ^a   Palmer, Brent E ^b   Banerjee, Anirban ^a   McCarter, Martin D ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Melanoma; Regulatory T cells; Thrombospondin; Tumor evasion

Indexed keywords

CD47 ANTIGEN; RECOMBINANT THROMBOSPONDIN 1; THROMBOSPONDIN 1; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; HELPER CELL; HUMAN; HUMAN CELL; IMMUNE RESPONSE; INCUBATION TEMPERATURE; INCUBATION TIME; MELANOMA; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN BLOOD LEVEL; RECEPTOR BLOCKING; REGULATORY T LYMPHOCYTE; TUMOR ESCAPE;

EID: 63049093346     PISSN: 18160735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Clark WH Jr, Elder DE, Guerry DT, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 81: 1893-1904, 1989.
2. Saleh F, Renno W, Klepacek I, Ibrahim G, Dashti H, Asfar S, Behbehani A, Al-Sayer H, Dashti A. Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anticancer vaccine. Curr Pharm Des 11: 3531-3543, 2005.
3. Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS. Tumorinfiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25: 869-875, 2007.
4. Riker AI, Radfar S, Liu S, Wang Y, Khong HT. Immunotherapy of melanoma: a critical review of current concepts and future strategies. Expert Opin Biol Ther 7: 345-358, 2007.
5. Anichini A, Vegetti C, Mortarini R. The paradox of T-cellmediated antitumor immunity in spite of poor clinical outcome in human melanoma. Cancer Immunol Immunother 53: 855-864, 2004.
6. Enk AH, Jonuleit H, Saloga J, Knop J. Dendritic cells as mediators of tumor-induced tolerance in metastatic melanoma. Int J Cancer 73: 309-316, 1997.
7. Gajewski TF, Meng Y, Harlin H. Immune suppression in the tumor microenvironment. J Immunother 29: 233-240, 2006.
8. Geertsen R, Hofbauer G, Kamarashev J, Yue FY, Dummer R. Immune escape mechanisms in malignant melanoma. Int J Mol Med 3: 49-57, 1999.
9. Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and nonself. Nat Immunol 6: 345-352, 2005.
10. Ziegler SF. FOXP3: of mice and men. Ann Rev Immunol 24: 209-226, 2006.
11. Gambineri E, Torgerson TR, Ochs HD. Immune dysregulation, polyendocrinopathy, enteropathy, and X-linked inheritance (IPEX), a syndrome of systemic autoimmunity caused by mutations of FOXP3, a critical regulator of T-cell homeostasis. Curr Opin Rheumatol 15: 430-435, 2003.
12. Haas J, Fritzsching B, Trubswetter P, Korporal M, Milkova L, Fritz B, Vobis D, Krammer PH, Suri-Payer E, Wildemann B. Prevalence of newly generated naïve regulatory T cells (Treg) is critical for Treg suppressive function and determines Treg dysfunction in multiple sclerosis. J Immunol 179: 1322-1330, 2007.
13. Sarkar S, Fox DA. Regulatory T cell defects in rheumatoid arthritis. Arthritis Rheum 56: 710-713, 2007.
14. Liyanage UK, Moore TT, Joo HG, Tanaka Y, Herrmann V, Doherty G, Drebin JA, Strasberg SM, Eberlein TJ, Goedegebuure PS, Linehan DC. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 169: 2756-2761, 2002.
15. Wolf AM, Wolf D, Steurer M, Gastl G, Gunsilius E, Grubeck-Loebenstein B. Increase of regulatory T cells in the peripheral blood of cancer patients. Clin Cancer Res 9: 606-612, 2003.
16. McCarter MD, Baumgartner J, Escobar GA, Richter D, Lewis K, Robinson W, Wilson C, Palmer BE, Gonzalez R. Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients. Ann Surg Oncol 14: 2854-2860, 2007.
17. Mourmouras V, Fimiani M, Rubegni P, Epistolato MC, Malagnino V, Cardone C, Cosci E, Nisi MC, Miracco C. Evaluation of tumour-infiltrating CD4+CD25+FOXP3+ regulatory T cells in human cutaneous benign and atypical naevi, melanomas and melanoma metastases. Br J Dermatol 157: 531-539, 2007.
18. Viguier M, Lemaitre F, Verola O, Cho MS, Gorochov G, Dubertret L, Bachelez H, Kourilsky P, Ferradini L. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173: 1444-1453, 2004.
19. Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 107: 929-934, 2001.
20. Crawford SE, Stellmach V, Murphy-Ullrich JE, Ribeiro SM, Lawler J, Hynes RO, Boivin GP, Bouck N. Thrombospondin-1 is a major activator of TGF-β1 in vivo. Cell 93: 1159-1170, 1998.
21. 1 integrin and CD47 differentially modulate T cell behavior. J Cell Biol 157: 509-519, 2002.
22. Grimbert P, Bouguermouh S, Baba N, Nakajima T, Allakhverdi Z, Braun D, Saito H, Rubio M, Delespesse G, Sarfati M. Thrombospondin/CD47 interaction: a pathway to generate regulatory T cells from human CD4+CD25- T cells in response to inflammation. J Immunol 177: 3534-3541, 2006.
23. Sid B, Sartelet H, Bellon G, El Btaouri H, Rath G, Delorme N, Haye B, Martiny L. Thrombospondin 1: a multifunctional protein implicated in the regulation of tumor growth. Crit Rev Oncol Hematol 49: 245-258, 2004.
24. Duggleby RC, Shaw TN, Jarvis LB, Kaur G, Gaston JS. CD27 expression discriminates between regulatory and nonregulatory cells after expansion of human peripheral blood CD4+ CD25+ cells. Immunology 121: 129-139, 2007.
25. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. Trends Cell Biol 11: 130-135, 2001.
26. Kosfeld MD, Frazier WA. Identification of a new cell adhesion motif in two homologous peptides from the COOH-terminal cell binding domain of human thrombospondin. J Biol Chem 268: 8808-8814, 1993.
27. Hoffmann HJ, Malling TM, Topcu A, Ryder LP, Nielsen KR, Varming K, Dahl R, Omland O, Sigsgaard T. CD4dimCD25bright Treg cell frequencies above a standardized gating threshold are similar in asthmatics and controls. Cytometry 71: 371-378, 2007.
28. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, Cerundolo V, Powrie F, Banham AH. Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the singlecell level. Eur J Immunol 35: 1681-1691, 2005.
29. Jaffe EA, Ruggiero JT, Leung LK, Doyle MJ, McKeown-Longo PJ, Mosher DF. Cultured human fibroblasts synthesize and secrete thrombospondin and incorporate it into extracellular matrix. Proc Natl Acad Sci USA 80: 998-1002, 1983.
30. Baumgartner J, Wilson C, Palmer B, Richter D, Banerjee A, McCarter M. Melanoma induces immunosuppression by upregulating FOXP3(+) regulatory T cells. J Surg Res 141: 72-77, 2007.
31. Annis DS, Murphy-Ullrich JE, Mosher DF. Function-blocking antithrombospondin-1 monoclonal antibodies. J Thromb Haemost 4: 459-468, 2006.
32. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 117: 1167-1174, 2007.
33. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163: 5211-5218, 1999.
34. Ahmad M, Rees RC, Ali SA. Escape from immunotherapy: possible mechanisms that influence tumor regression/progression. Cancer Immunol Immunother 53: 844-854, 2004.
35. Nair RE, Kilinc MO, Jones SA, Egilmez NK. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors. J Immunol 176: 7325-7334, 2006.
36. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 107: 628-636, 2006.
37. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M, Zhu Y, Wei S, Kryczek I, Daniel B, Gordon A, Myers L, Lackner A, Disis ML, Knutson KL, Chen L, Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10: 942-949, 2004.
38. Gray CP, Arosio P, Hersey P. Heavy chain ferritin activates regulatory T cells by induction of changes in dendritic cells. Blood 99: 3326-3334, 2002.
39. Liu VC, Wong LY, Jang T, Shah AH, Park I, Yang X, Zhang Q, Lonning S, Teicher BA, Lee C. Tumor evasion of the immune system by converting CD4+CD25- T cells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J Immunol 178: 2883-2892, 2007.
40. Kikuchi Y, Uno S, Kinoshita Y, Yoshimura Y, Iida S, Wakahara Y, Tsuchiya M, Yamada-Okabe H, Fukushima N. Apoptosis inducing bivalent single-chain antibody fragments against CD47 showed antitumor potency for multiple myeloma. Leuk Res 29: 445-450, 2005.
41. Uno S, Kinoshita Y, Azuma Y, Tsunenari T, Yoshimura Y, Iida S, Kikuchi Y, Yamada-Okabe H, Fukushima N. Antitumor activity of a monoclonal antibody against CD47 in xenograft models of human leukemia. Oncol Rep 17: 1189-1194, 2007.
42. Trotter MJ, Colwell R, Tron VA. Thrombospondin-1 and cutaneous melanoma. J Cutan Med Surg 7: 136-141, 2003.
43. Qian X, Tuszynski GP. Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med (New York) 212: 199-207, 1996.
44. Hoekstra R, de Vos FY, Eskens FA, Gietema JA, van der Gaast A, Groen HJ, Knight RA, Carr RA, Humerickhouse RA, Verweij J, de Vries EG. Phase I safety, pharmacokinetic, and pharmacodynamic study of the thrombospondin-1-mimetic angiogenesis inhibitor ABT-510 in patients with advanced cancer. J Clin Oncol 23: 5188-5197, 2005.
45. Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 30: 303-309, 2007.
46. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Acta Biochim Biophys Hung 1765: 178-188, 2006.
47. Cooper D, Lindberg FP, Gamble JR, Brown EJ, Vadas MA. Transendothelial migration of neutrophils involves integrinassociated protein (CD47). Proc Natl Acad Sci USA 92: 3978-3982, 1995.
48. Saumet A, de Jesus N, Legrand C, Dubernard V. Association of thrombospondin-1 with the actin cytoskeleton of human thrombin-activated platelets through an αIIbβ3- or CD36-independent mechanism. Biochem J 363(Pt 3): 473-482, 2002.
49. Futagami Y, Sugita S, Vega J, Ishida K, Takase H, Maruyama K, Aburatani H, Mochizuki M. Role of thrombospondin-1 in T cell response to ocular pigment epithelial cells . J Immunol 178: 6994-7005, 2007.
50. Belghith M, Bluestone JA, Barriot S, Megret J, Bach JF, Chatenoud L. TGF-β-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 9: 1202-1208, 2003.
51. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol 6: 1142-1151, 2005.
52. Hubert P, Jacobs N, Caberg JH, Boniver J, Delvenne P. The cross-talk between dendritic and regulatory T cells: good or evil? J Leukoc Biol 82: 781-794, 2007.
53. Marteau F, Gonzalez NS, Communi D, Goldman M, Boeynaems JM, Communi D. Thrombospondin-1 and indoleamine 2,3-dioxygenase are major targets of extracellular ATP in human dendritic cells. Blood 106: 3860-3866, 2005.